Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Stempeutics gets...

    Stempeutics gets patent for stem cell drug Stempeucel from US Patent and Trademarks Office

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-03T09:55:00+05:30  |  Updated On 17 Aug 2021 12:06 PM IST

    "The US patent is for the method of treating ischemia by administering pooled allogeneic mesenchymal stromal cells," Stempeutics Research said in a statement.


    New Delhi: Biotech firm Stempeutics Research on Friday said United States Patent and Trademarks Office (USPTO) has granted a patent to the company for its innovative stem cell drug Stempeucel for treating Critical Limb Ischemia. Critical Limb Ischemia is a severe blockage in the arteries which results in reduced blood flow which in turn may result in a poor quality of life with a high risk of leg amputation and death.


    "The US patent is for the method of treating ischemia by administering pooled allogeneic mesenchymal stromal cells," Stempeutics Research said in a statement.


    Stempeucel is derived from allogeneic pooled mesenchymal stromal cells extracted from the bone marrow of healthy, adult voluntary donors, it added.


    Read Also: Cipla, Stempeutics ink licensing deal for Stempeucel-DFU to treat a diabetic foot ulcer


    "This very important patent comes at the right time, just ahead of our planned Pre-Investigational New Drug Application (PreIND) meeting with the United States Food and Drug Administration (USFDA)," Stempeutics CEO B N Manohar said.


    The patent is being granted by USPTO is a strong recognition for Stempeutics for its sustained excellence of scientific and clinical work and underscores the global leadership in allogeneic, pooled MSC technology, he added.


    Stempeutics Research, a group company of Manipal Education and Medical Group, seeks to develop novel stem cell drugs addressing major unmet medical needs.


    Read Also: Manipal Group Stempeutics, Kemwell strike a deal worth Rs 95 crore for global commercialisation of Stempeucel

    B N Manoharbiotech firmclinical workcritical limb ischemiadrug patentHealthcareManipal EducationManipal Groupmedicalmesenchymal stromal cellNew Drug Applicationpatent grantpharmastem cell drugStempeucelStempeuticsStempeutics Researchus patentUS Patent and Trademarks OfficeUSFDAUSPTO
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok